References
- European Association for the Study of the Liver EASL clinical practice guidelines: Management of chronic hepatitis B virus infection J Hepatol 2012 57 167 185 22436845
- Keating GM Entecavir: a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease Drugs 2011 71 2511 2529 22141390
- Zoutendijk R Reijnders JG Brown A Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response Hepatology 2011 54 443 451 21563196
- Khungar V Han SH A systematic review of side effects of nucleoside and nucleotide drugs used for treatment of chronic hepatitis B Curr Hepatitis Rep 2010 9 75 90
- Yuen MF Seto WK Fung J Wong DK Yuen JC Lai CL Three years of continuous Entecavir therapy in treatment-naive chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety Am J Gastroenterol 2011 106 1264 1271 21364549
- Yurdaydın C Entecavir: a step forward in combating hepatitis B disease Expert Opin Pharmacother 2008 9 3095 3109 19006481
- Baldick CJ Eggers BJ Fang J Hepatitis B virus quasispecies susceptibility to Entecavir confirms the relationship between genotypic resistance and patient virologic response J Hepatol 2008 48 895 902 18362040
- Chang TT Lai CL Kew Yoon S Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B Hepatology 2010 51 422 430 20049753
- Shouval D Lai CL Chang TT Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful Entecavir treatment: the case for continuous antiviral therapy J Hepatol 2009 50 289 295 19070393
- Zoutendijk R Reijnders JG Zoulim F Virological response to Entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis Gut 2013 62 760 765 22490523
- Hadziyannis SJ Tassopoulos NC Heathcote EJ Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B N Engl J Med 2005 352 2673 2681 15987916
- Santantonio T Mazzola M Iacovazzi T Miglietta A Guastadisegni A Pastore G Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine J Hepatol 2000 32 300 306 10707871
- Pol S Lampertico P First-line treatment of chronic hepatitis B with Entecavir or tenofovir in ‘real-life’ settings: from clinical trials to clinical practice J Viral Hepat 2012 19 377 386 22571899
- Ha NB Ha NB Chaung KT Similar response to Entecavir 0.5 and 1.0 mg in treatment-naïve chronic hepatitis B patients: a case-control study Dig Dis Sci 2014 59 1 168 173 24248420
- Chang TT Gish RG Hadziyannis SJ A dose-ranging study of the efficacy and tolerability of Entecavir in lamivudine-refractory chronic hepatitis B patients Gastroenterology 2005 129 1198 1209 16230074
- Tenney DJ Rose RE Baldick CJ Long-term monitoring shows hepatitis B virus resistance to Entecavir in nucleoside-naive patients is rare through 5 years of therapy Hepatology 2009 49 1503 1514 19280622
- Gish RG Chang TT Lai CL Loss of HBsAg antigen during treatment with Entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B J Viral Hepat 2010 17 16 22 19622117
- Marcellin P Heathcote EJ Buti M Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B N Engl J Med 2008 359 2442 2455 19052126
- Heathcote EJ Marcellin P Buti M Three-year efficacy and safety of tenofovir disoproxilfumarate treatment for chronic hepatitis B Gastroenterology 2011 140 132 143 20955704
- Marcellin P Buti M Gane EJ Five years of treatment with tenofovir DF (TDF) for chronic hepatitis B (CHB) infection is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis: Proceedings of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases, San Fransisco, CA, USA, 6–9 November 2011 Available from: http://www.natap.org/2011/AASLD/AASLD_47.htm Accessed April 30, 2014
- Yuen MF Lai CL Treatment of chronic hepatitis B: Evolution over two decades J Gastroenterol Hepatol 2011 26 Suppl 1 138 143 21199525